Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alan Trumbly

Hematology & Oncology Richardson, TX Doctor of Osteopathy

NPI 1417121286 CMS profile 199798

2805 E President George Bush Hwy, Richardson, TX 75082

Open in the dashboard

General payments

$6,093

196 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$52,912 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Alan Trumbly of Richardson, TX is reported in the CMS Open Payments database as having received $6,093 across 196 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $52,912 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 63rd percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,978 39
2024 General $847 29
2023 General $812 24
2022 General $644 21
2021 General $91 6
2020 General $426 16
2019 General $1,295 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alan Trumbly
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Alan Trumbly were reported at $1,978. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Alan Trumbly Hematology & Oncology median Middle half National median
2019 $1,295 $529 $121–$2,516 $163
2020 $426 $339 $82–$2,213 $114
2021 $91 $263 $49–$1,965 $132
2022 $644 $416 $103–$2,395 $149
2023 $812 $542 $125–$2,646 $160
2024 $847 $692 $141–$3,008 $164
2025 $1,978 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,723 24 payments
  2. Novocure Inc. $734 8 payments
  3. Janssen Biotech, Inc. $331 13 payments
  4. AstraZeneca Pharmaceuticals LP $269 13 payments
  5. Pfizer Inc. $206 12 payments
  6. Genzyme Corporation $193 4 payments
  7. E.R. Squibb & Sons, L.L.C. $165 10 payments
  8. Davol Inc. $136 1 payment
  9. Gilead Sciences, Inc. $135 6 payments
  10. Merck Sharp & Dohme Corporation $130 8 payments
  11. Other $2,070 97 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,273 175 payments
  2. Long term medical supply or device loan $1,595 16 payments
  3. Education $224 5 payments
Products named General payments · program years 2019–2025
  1. KISQALI $1,347 16 payments
  2. Optune Oncology $255 2 payments
  3. Optune Oncology $182 2 payments
  4. Optune Gio $160 1 payment
  5. SARCLISA $141 1 payment
  6. Oncology $137 3 payments
  7. PHASIX $136 1 payment
  8. KEYTRUDA $130 8 payments
  9. IMBRUVICA $130 4 payments
  10. SIR-Spheres Microspheres $118 2 payments
  11. Other $3,566 188 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 71 drugs

Part D claims

2,956

Median for Hematology-Oncology: 604

Drug cost

$3,564,568

Median for Hematology-Oncology: $1,306,514

Branded share of claims

23.8%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lenalidomide Generic 54 $671,830
Lenvima Lenvatinib Mesylate Brand 26 $633,446
Cabometyx Cabozantinib S-Malate Brand 17 $483,372
Calquence Acalabrutinib Maleate Brand 17 $234,790
Alecensa Alectinib Hcl Brand 12 $225,136
Revlimid Lenalidomide Brand 16 $212,449
Tagrisso Osimertinib Mesylate Brand 12 $192,363
Lynparza Olaparib Brand 12 $188,944
Verzenio Abemaciclib Brand 12 $185,658
Jakafi Ruxolitinib Phosphate Brand 12 $148,461

The 10 drugs with the highest cost, of 71 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$118,584

Medicare's payments for the services billed

Medicare patients

457

Average age 75

Services billed

1,468

295 women, 162 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 59%
Arthritis 45%
Diabetes 34%
Chronic kidney disease 33%
Osteoporosis 30%
Ischemic heart disease 27%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBREVANT
  • Janssen Biotech, Inc. $52
$52 — —
BESREMI
  • PharmaEssentia USA Corporation $52
$52 — —
ENHERTU
  • AstraZeneca Pharmaceuticals LP $27
  • Daiichi Sankyo Inc. $15
$41 — —
ZEPZELCA
  • JAZZ PHARMACEUTICALS INC. $32
$32 — —
XPOVIO
  • Karyopharm Therapeutics Inc. $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

196 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record